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Abstract
Background Colonoscopy may be one of the most frequent
elective procedures in older adults and is associated with a
low occurrence of complications. However, reduction of
risks attributable to the bowel preparation may be achieved
with the use of effective and safer products.
Aim The aim of this study was to examine the incidence of
treatment-emergent adverse events (TEAEs) associated
with SUPREP [oral sulfate solution (OSS)] and other
common prescription bowel preparations (non-OSS).
Methods This real-world, observational study used de-
identified health insurance claims and laboratory results to
identify TEAEs in the 3 months following screening
colonoscopy in adults with a prescription for a bowel
preparation in the prior 60 days. The unadjusted and
adjusted (controlling for patient risk factors) cumulative
incidences of TEAEs were estimated using Kaplan–Meier
and Poisson regression, respectively.
Results Among patients C45 years, the overall cumulative
incidence was significantly lower (p\ 0.001) in the OSS
cohort than in the non-OSS cohort (unadjusted: 2.31 vs.
2.89 %; adjusted: 1.61 vs. 1.95 %), with significantly lower
acute cardiac conditions (1.56 vs. 1.90 %; p\ 0.001), renal
failure/other serious renal diseases (OSS: 0.21 %, non-OSS:
0.32 %; p\ 0.001), and serum electrolyte abnormalities
(OSS: 0.39 %, non-OSS: 0.49 %; p = 0.017). Therewere no
significant differences between cohorts in death, seizure
disorders, aggravation of gout, and ischemic colitis. Results
were similar in the adjusted cumulative incidences.
Conclusions In actual use, the overall cumulative inci-
dence of TEAEs was significantly lower in the OSS cohort,
demonstrating that OSS is as safe as, or possibly safer than,
non-OSS prescription bowel preparations.
Keywords Colonoscopy  Bowel preparation  Adverse
event
Introduction
Colonoscopy may be one of the most frequent elective
procedures, particularly in adults aged 45 years and older
in which it is part of a recommended colorectal cancer
screening program [1]. Complications from colonoscopy
and the bowel preparation that precedes the procedure
occur at a low frequency [2]; however, reduction of risks
that are attributable to the bowel preparation may be
achieved with the use of effective and safer products [3].
To date, the safest bowel preparations are generally
recognized to be the isotonic formulations composed of
polyethylene glycol (PEG) and electrolytes, which have
been in use since the early 1980s. These preparations
induce a voluminous osmotic diarrhea and are designed to
prevent electrolyte and water gains or losses [4, 5]. How-
ever, adequate cleansing for colonoscopy with these
preparations requires ingestion of a large volume of solu-
tion, typically about 4 L. In response to patient demands
for lower volume and more tolerable preparations, a small
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volume hypertonic saline preparation based on sodium
phosphate was promoted in the 1990s [6]. This product
similarly induced an osmotic diarrhea, but unlike the
isosmotic preparations, supplemental water was required to
prevent dehydration. Rare case reports of acute renal fail-
ure eventually emerged followed by publication of kidney
biopsy data showing renal calcification in association with
use of the phosphate preparations [7]. The United States
(US) Food and Drug Administration (FDA) subsequently
issued a warning resulting in the voluntary removal from
the market of the liquid form of the sodium phosphate
bowel preparation and a ‘‘black box’’ warning for the tablet
preparations [8].
A new hypertonic saline preparation has been introduced
based on a combination of the sulfate salts of sodium,
potassium, andmagnesium (SUPREP [oral sulfate solution
(OSS)], Braintree Laboratories Inc.) [9]. Studies of the
physiology of both phosphate and sulfate hypertonic prepa-
rations in normal volunteers showed that the use of the
phosphate preparation, but not the sulfate formulation,
markedly increased urine phosphate concentration with a
corresponding increase in propensity for formation of cal-
cium precipitates, despite vigorous hydration of study sub-
jects [10]. Clinical studies of the sulfate formulation have
demonstrated its safety and efficacy under the rigorous
conditions inherent in formal clinical trials where it appears
to be equally safe to the PEG-based preparations [9–11].
However, real-world clinical experience can vary in ways
not observed within the confines of clinical trials. For
example, based on the phosphate experience, because the
product requires ingestion of supplemental water to replace
fluid loss induced by the osmotic diarrhea, somepatientsmay
not consume sufficient replacement water, which results in
problems associated with dehydration. Additionally, rare
unanticipated outcomes are more likely to be detected in
large, observational studies.
This study compared the incidence of treatment-emer-
gent adverse events (TEAEs) which may occur in associ-
ation with the recently approved OSS bowel preparation to
other common bowel preparations in patients aged
45 years or older who underwent screening colonoscopy.
This is the first report that examines the incidence of
TEAEs in clinical practice for any bowel preparation to
other available prescription bowel preparations in a large
population of screening patients.
Methods
Study Design
This retrospective, real-world, observational study was
undertaken as a post-marketing pharmacovigilance safety
study of OSS in screening colonoscopy patients. The study
was approved by the New England Institutional Review
Board and was agreed by the FDA. Data were obtained
from a de-identified health insurance claims data source
(MarketScan Commercial Claims and Encounters Data-
base and Medicare Supplemental and Coordination of
Benefits Database, Truven Health Analytics, Inc.). Labo-
ratory results data were also obtained (Truven Health
Analytics, Inc.). Health insurance claims included inpa-
tient, outpatient, and prescription drug claims for over 170
million individuals in the USA annually from approxi-
mately 90 large employers and health plans, with insurance
provided under various fee-for-service and capitated health
plans. The data include commercially insured beneficiaries
aged 0–64 years and beneficiaries aged 65 and older with
Medicare coverage in addition to commercial insurance.
The study period included claims from August 1, 2009,
through December 31, 2011, with an observation period
from August 1, 2010, through December 31, 2011.
The primary objective was to describe and compare, in
real-world settings, the incidence of TEAEs observed
associated with OSS to other prescription bowel prepara-
tions occurring at any time in the 3 months following
administration for screening colonoscopy in an adult pop-
ulation in the USA.
Study Population
Patients who received a bowel preparation followed by a
screening colonoscopy were included in the study.
Specifically, patients who met the following criteria were
included:
• had a claim for a screening colonoscopy;
• had a claim for one of the following bowel preparations
within the 60 days prior to the screening colonoscopy:
OSS (i.e., SUPREP); PEG-3350 and electrolytes for
oral solution (generic or Clenz-LyteTM [Paddock Lab-
oratories Inc.], Colyte [Meda Pharmaceuticals Inc.],
GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLytely
[Braintree Laboratories Inc.], HalfLytely [Braintree
Laboratories Inc.], Moviprep [Salix Pharmaceuticals
Inc.], NuLytely [Braintree Laboratories Inc.], Trilyte
[Wallace Pharmaceuticals]); sodium phosphate
monobasic monohydrate, USP, and sodium phosphate
dibasic anhydrous, USP (Osmoprep, Salix Pharma-
ceuticals Inc.), or sodium phosphate monobasic mono-
hydrate, sodium phosphate dibasic anhydrous
(Visicol, Salix Pharmaceuticals Inc.);
• had been continuously enrolled in their insurance plan
during the 12 months prior to and 3 months following
and including the administration of the bowel prepara-
tion; and
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• were 18 years of age or older on the day of the
administration of the bowel preparation.
Patients were excluded from the study if they had a
claim that included:
• a prescription for both OSS and one of the other bowel
preparations within the 60 days prior to screening
colonoscopy (excluded from primary analysis); or
• evidence that the colonoscopy was not a screening
colonoscopy such as:
– a colon polypectomy in the 12 months prior to the
administration of the bowel preparation; or
– a diagnosis of a gastrointestinal cancer (including
colon, esophagus, rectum, small intestine, and stomach)
during the 12 months prior to the administration of the
bowel preparation.
Screening colonoscopy procedures were identified by
the following Healthcare Common Procedure Coding
System (HCPCS) codes or combined Current Procedural
Terminology (CPT) and International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM)
diagnosis codes [12]:
• HCPCS: G0105 (colorectal cancer screening; colono-
scopy on individual at high risk).
• HCPCS: G0121 (colorectal cancer screening; colono-
scopy on individual not meeting criteria for high risk).
• CPT: 45378 (colonoscopy, flexible, proximal to splenic
flexure; with or without colon decompression), 45380
(colonoscopy, flexible, proximal to splenic flexure;
with biopsy), 45384 (colonoscopy, flexible, proximal to
splenic flexure; with removal of tumor, polyp, or other
lesion by hot biopsy forceps or bipolar cautery), 45385
(colonoscopy, flexible, proximal to splenic flexure;
with removal of tumor, polyp, or other lesions by snare
technique), or 45392 (colonoscopy, flexible, proximal
to splenic flexure; with transendoscopic ultrasound-
guided intramural or transmural fine needle aspiration/
biopsy) and ICD-9-CM diagnosis code: V76.51 (special
screening for malignant neoplasm—colon) or V16.0
(family history of malignant neoplasm—gastrointesti-
nal tract).
The bowel preparations were identified by National
Drug Code.
Patients meeting the inclusion and exclusion criteria
who had a prescription claim for OSS were included in the
OSS cohort. Patients with a prescription claim for one of
the other bowel preparations were included in the non-OSS
cohort.
Identification of TEAEs
A TEAE was defined as an event that occurred any time in
the 3 months following administration of the bowel
preparation for a screening colonoscopy (i.e., follow-up
period) and did not occur in the 12 months prior to
administration (i.e., baseline period). The 3-month period
following administration was chosen as an appropriate
follow-up period to observe the TEAEs of interest, par-
ticularly renal failure. This period is two months longer
than the observation period in a study of safety of bowel
preparations in the Medicare population [12]. A 3-month
period was expected to be adequate, as most cases (85.7 %)
of acute renal failure occur during the first 2 months after
oral phosphate solution [7]. TEAEs that were examined
have been historically associated with bowel preparations
and were identified by primary and secondary ICD-9-CM
diagnosis codes or out-of-range laboratory values [13].
TEAEs identified by diagnosis codes included ischemic
colitis [14], aggravation of gout, acute cardiac conditions
or events, renal failure and other serious renal diseases,
seizure disorders, and serum electrolyte abnormalities.
TEAEs identified by laboratory values included troponin
leak, elevated creatinine kinase, serum electrolyte abnor-
malities, and serum uric acid. The codes used to identify
the TEAEs are provided in Exhibit 1 of Appendix. Death
was identified within the inpatient setting using an indi-
cator for death on the discharge status of the inpatient
claim.
Patient risk factors associated with the TEAEs were also
identified by ICD-9-CM diagnosis codes during the base-
line period. These included arteriosclerosis, brain cancer,
diabetes mellitus, gout, heart failure, hyperlipidemia,
hypertension, hypotension, liver disease, obesity, periph-
eral artery disease, previous abdominal surgery (colec-
tomy, colostomy, gastric bypass, stomach stapling), renal
disease, stroke, thiazide diuretics use, thyroid disease, and
vasculitis [15].
Analytic Methods
Descriptive statistics (i.e., means, standard deviations,
medians, ranges) on the demographic and clinical risk
factors observed prior to the administration of the bowel
preparation were calculated for each bowel preparation
cohort (i.e., OSS and non-OSS). To examine the incidence
of each TEAE in real-world settings, the unadjusted
cumulative incidence of each TEAE and a 95 % confidence
interval (CI) were calculated using the Kaplan–Meier
method. Differences between the two cohorts were tested
using the log-rank Chi-square. To account for any
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differences between the two cohorts in demographic or
clinical risk factors prior to the administration of the bowel
preparation, an adjusted cumulative incidence was calcu-
lated for each TEAE. Adjusted cumulative incidences and
95 % CIs were calculated using Poisson regression, con-
trolling for demographic and clinical risk factors poten-
tially associated with the bowel preparation and each
TEAE, as applicable. The clinical risk factors included in
the Poisson regression for each TEAE are provided in
Exhibit 1 of Appendix. Demographic and clinical risk
factors were removed from the Poisson model if its
parameter estimate was not significant (i.e., p value greater
than 0.10). Follow-up time was used as on offset in the
Poisson regression. Differences in the adjusted incidences
between the two cohorts were tested using the Wald Chi-
square from the Poisson regression. When no events were
observed within a cohort, the Clopper–Pearson method was
used to calculate an exact 95 % CI. The Fisher’s exact test
was used to calculate a p value when no events were
observed in either cohort. Patients with less than 3 months
of follow-up due to death, but had no other TEAEs, were
censored for the calculation of incidence of each TEAE
other than death. The Benjamini–Hochberg false discovery
rate procedure [16, 17] was used to control for multiple
comparisons for the unadjusted and adjusted incidences in
the main analysis, maintaining a type I error rate of 0.05
which resulted in a claim of significance if the p value was
less than 0.018 among the unadjusted incidences and less
than 0.014 among the adjusted incidences.
The main analysis focused on patients aged 45 years or
older because screening colonoscopy is indicated for this
age group [1]. A secondary analysis examined patients
aged 18–44 years. Analyses were performed using SAS
Software, version 9.1 or higher (SAS Institute, Cary, North
Carolina).
Results
A total of 835,219 patients were identified as having a
screening colonoscopy during the study period. Figure 1
presents the effect of the inclusion and exclusion criteria on
the study population. Approximately 25 % of patients were
excluded because they were not continuously enrolled
during the 12 months prior to and 3 months following and
including the administration of the bowel preparation so
their TEAEs could not be assessed. Another 39 % of
patients were excluded because they had no pharmacy
claim for a prescription bowel preparation, perhaps due to
the physician providing bowel preparation samples and/or
recommending over-the-counter products. Thus, just over
one-third (35.8 %) of these patients met the inclusion and
exclusion criteria for this study, with 287,323 (96.0 %) of
these patients aged 45 years or older (OSS: 31,885; non-
OSS: 255,438).
Demographic and clinical characteristics of these
patients are presented in Table 1. The average age of
patients was slightly lower in the OSS cohort compared to
the non-OSS cohort (56.6 vs. 57.5 years; p\ 0.001)
(Table 2). The percent of males was similar between the
two cohorts (OSS: 47.1 %, non-OSS: 46.7 %; p = 0.178).
The most common (C5 %) TEAE risk factors were arte-
riosclerosis, diabetes, hyperlipidemia, hypertension, thi-
azide diuretics use, and thyroid disease. For each TEAE
risk factor, except brain cancer, previous abdominal sur-
gery, thyroid disease, and vasculitis, the percent of patients
differed significantly (p\ 0.05) between cohorts; however,
the difference was approximately 2 % or less for all TEAE
risk factors.
Main Analysis
Unadjusted Incidence
The unadjusted cumulative incidences of the TEAE cate-
gories identified by diagnosis codes are presented in
Table 2, and the incidences of the individual TEAEs that
made up the categories are presented in Exhibit 2 of
Appendix. The overall cumulative incidence was signifi-
cantly lower in the OSS cohort (2.31 vs. 2.89 %;
p\ 0.001).
Among the TEAE categories, the incidence of acute
cardiac conditions was also significantly lower in the OSS
cohort (1.56 vs. 1.90 %; p\ 0.001) with the majority of
patients with acute cardiac events experiencing arrhythmia
(OSS: 230 [46.1 %], non-OSS: 2250 [46.4 %]; Appendix,
Exhibit 2) followed by abnormal electrocardiogram (OSS:
141 [28.3 %], non-OSS: 1465 [30.2 %]; Appendix, Exhibit
2). Additionally, renal failure/other serious renal diseases
(OSS: 0.21 %, non-OSS: 0.32 %; p\ 0.001) and serum
electrolyte abnormalities (OSS: 0.39 %, non-OSS: 0.49 %;
p = 0.017) were significantly lower in the OSS cohort.
The cumulative incidences were not significantly dif-
ferent for the following other TEAE categories: seizure
disorders (OSS: 0.27 %, non-OSS: 0.34 %; p = 0.040),
aggravation of gout (OSS: 0.24 %, non-OSS: 0.28 %;
p = 0.151), death (OSS: 0.01 %, non-OSS: 0.02 %;
p = 0.366), and ischemic colitis (OSS: 0.02 %, non-OSS:
0.02 %; p = 0.722).
Among the patients with laboratory data (OSS: 653 and
non-OSS: 14,432), the incidences were also not signifi-
cantly different for the TEAE categories of serum elec-
trolyte abnormalities/serum uric acid (OSS: 0.92 %, non-
OSS: 1.52 %; p = 0.218), elevated creatine kinase (OSS:
0.00 %, non-OSS: 0.03 %; p = 1.000), and troponin leak
(OSS: 0.00 %, non-OSS: 0.00 %; p = 1.000).
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Adjusted Incidence
The adjusted cumulative incidences of the TEAEs identi-
fied by diagnosis codes are presented in Table 3, and the
incidences of the individual TEAEs that made up the cat-
egories are presented in Exhibit 3 of Appendix. The overall
cumulative incidence was significantly lower in the OSS
cohort (1.61 vs. 1.95 %; p\ 0.001). Among the TEAE
categories, the incidence of acute cardiac conditions (1.23
vs. 1.47 %; p\ 0.001) and renal failure/other serious renal
diseases (OSS: 0.10 %, non-OSS: 0.15 %; p = 0.004) was
also significantly lower in the OSS cohort. The cumulative
incidences were not significantly different, for the
following other TEAE categories: seizure disorders (OSS:
0.26 %, non-OSS: 0.32 %; p = 0.046), serum electrolyte
abnormalities (OSS: 0.34 %, non-OSS: 0.41 %;
p = 0.048), aggravation of gout (OSS: 0.12 %, non-OSS:
0.14 %; p = 0.233), death (OSS: 0.01 %, non-OSS:
0.02 %; p = 0.369), and ischemic colitis (OSS: 0.02 %,
non-OSS: 0.02 %; p = 0.743).
Among the patients with laboratory data, the incidences
were not significantly different for the TEAE categories of
serum electrolyte abnormalities/serum uric acid (OSS:
0.86 %, non-OSS: 1.37 %; p = 0.257), elevated creatine
kinase (OSS: 0.00 %, non-OSS: 0.03 %; p = 1.000), and
troponin leak (OSS: 0.00 %, non-OSS: 0.00 %; p = 1.000).
45+ years of age
N = 287,323 (96.0%) 
OSS: N = 31,885 
non-OSS: N = 255,438 
Claim for screening colonoscopy 
N = 835,219
At least 18 years of age
N = 834,7191
Continuously enrolled 
during the 12 months prior to and 3 months following and 
including the administration of the bowel preparation
N = 625,795 (74.9%)
Claim for one of the bowel preparations3
in the 60 days prior to administration
N = 299,417 (35.8%)
Abbreviations: HIC = health insurance claims; EMR = electronic medical records
1 Age distribution: 36,461 (4.4%) age 18 – 44; 798,258 (95.6%) age 45+
2 Age distribution: 1,254 (4.2%) age 18 – 44; 28,445 (95.8%) age 45+
3 Bowel preparations include the following: OSS (i.e., SUPREP), Clenz-Lyte™, Colyte®, GaviLyte-C, 
GaviLyte-G, GaviLyte-N, GoLytely®, HalfLytely®, Moviprep®, NuLytely®, Osmoprep® , Polyethylene 
glycol 3350 and electrolytes, Trilyte®, or Visicol®
18-44 years of age
N = 12,094 (4.0%) 
OSS: N= 1,580  
non-OSS: N = 10,514 
Fig. 1 Study population
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Secondary Analyses
Among patients aged 18–44 years (OSS: 1580, non-OSS:
10,514), the overall cumulative incidences of TEAEs,
identified by diagnosis codes, were similar between the two
cohorts for both the unadjusted estimate (OSS: 1.33 %
[95 % CI 0.87, 2.03], non-OSS: 1.46 [95 % CI 1.25, 1.71];
p = 0.675) and the adjusted estimate (OSS: 1.20 [95 % CI
0.78, 1.85], non-OSS: 1.30 [95 % CI 1.09, 1.55];
p = 0.721). Among patients with laboratory data (OSS: 26
Table 1 Demographic and
baseline clinical risk factors of
an adult screening colonoscopy
population
Characteristic OSS (N = 31,885) non-OSS (N = 255,438)
Age, mean (sd) 56.6 (6.4) 57.5 (7.3)
Male, n (%) 15,026 (47.1) 119,357 (46.7)
TEAE risk factors
Arteriosclerosis, n (%) 1657 (5.2) 15,704 (6.1)
Brain cancer, n (%) 12 (0.0) 114 (0.0)
Diabetes, n (%) 3982 (12.5) 35,687 (14.0)
Heart failure, n (%) 237 (0.7) 2646 (1.0)
Hyperlipidemia, n (%) 12,397 (38.9) 100,904 (39.5)
Hypertension, n (%) 10,836 (34.0) 92,760 (36.3)
Hypotension, n (%) 125 (0.4) 1357 (0.5)
Liver disease, n (%) 871 (2.7) 7503 (2.9)
Obesity, n (%) 838 (2.6) 8285 (3.2)
Peripheral artery disease, n (%) 247 (0.8) 2414 (0.9)
Previous abdominal surgery, n (%) 970 (3.0) 7735 (3.0)
Stroke, n (%) 811 (2.5) 7545 (3.0)
Thiazide diuretics use, n (%) 1808 (5.7) 17,424 (6.8)
Thyroid disease, n (%) 4013 (12.6) 31,862 (12.5)
Vasculitis, n (%) 52 (0.2) 378 (0.1)
TEAE treatment-emergent adverse event
Table 2 Unadjusted incidence of treatment-emergent adverse events associated with bowel preparations in an adult screening colonoscopy
population
Treatment-emergent adverse event OSS (N = 31,885) Non-OSS (N = 255,438) p value
n Incidence (%) 95 % CI n Incidence (%) 95 % CI
Identified by diagnosis codes
Overall 736 2.31 2.15, 2.48 7374 2.89 2.82, 2.95 \0.001
Acute cardiac conditions or events 499 1.56 1.43, 1.71 4845 1.90 1.84, 1.95 \0.001
Aggravation of gout 75 0.24 0.19, 0.29 715 0.28 0.26, 0.30 0.151
Death 3 0.01 0.00, 0.03 41 0.02 0.01, 0.02 0.366
Ischemic colitis 6 0.02 0.01, 0.04 56 0.02 0.02, 0.03 0.722
Renal failure and other serious renal diseases 67 0.21 0.17, 0.27 817 0.32 0.30, 0.34 \0.001
Seizure disorders 85 0.27 0.22, 0.33 859 0.34 0.31, 0.36 0.040
Serum electrolyte abnormalities 125 0.39 0.33, 0.47 1253 0.49 0.46, 0.52 0.017
Identified by laboratory values N = 653 N = 14,432
Elevated creatine kinase 0 0.00 0.00, 0.56 5 0.03 0.01, 0.08 1.000
Serum electrolyte abnormalities and serum uric acid 6 0.92 0.41, 2.03 219 1.52 1.33, 1.73 0.218
Troponin leak 0 0.00 0.00, 0.56 0 0.00 0.00, 0.03 1.000
The unadjusted cumulative incidence of each TEAE was calculated using the Kaplan–Meier method. Differences between the two cohorts were
tested using the log-rank Chi-square test. When there were no events observed, the Clopper–Pearson method was used to calculate exact CIs. The
Fisher’s exact test was used to calculate the p value for troponin leak
CI confidence interval
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and non-OSS: 582), no TEAEs were observed in the OSS
cohort and nine TEAEs were observed in the non-OSS
cohort for serum electrolyte abnormalities/serum uric acid.
Relative to patients aged 45 years or older, patients aged
18 to 44 years had lower overall unadjusted cumulative
incidence of TEAEs identified by diagnosis codes in the
OSS cohort (age 18–44: 1.33 [95 % CI 0.87, 2.03]; age
45 ? : 2.31 [95 % CI 2.15, 2.48]) and in the non-OSS
cohort (age 18–44: 1.46 [95 % CI 1.25, 1.71], age 45 ? :
2.89 [2.82, 2.95]).
Discussion
To our knowledge, this is the largest study of post-colo-
noscopy TEAEs and the first to compare incidences of
these TEAEs between any prescription bowel preparation
product and its peers, using real-world data. This study
used ICD-9 diagnosis and procedure codes appearing on
health insurance claims to define just over half of the
TEAEs. ICD-9 codes are recorded for billing purposes and
were not developed for research studies. However, it has
been shown that ICD-9 codes recorded in administrative
claims have extremely high specificity in both ambulatory
and inpatient settings [18–20]. The other TEAEs were
defined by laboratory tests.
There is a growing need to measure results from real-
world clinical practice. Randomized clinical trials typically
measure short-term efficacy and safety of a product in a
fairly homogenous population and under ideal, controlled
conditions compared to placebo. In contrast, real clinical
practice requires patient care of a heterogeneous population
which is much less controlled and thus more complex.
Treatment decisions made in the real clinical practice must
consider a wider array of comorbid conditions, competing
medications, physician preference, and possible adverse
events that may be observed in a larger population or over a
longer period of time than included in clinical trials. Out-
comes observed in real-world settings reflect this com-
plexity and complement the results observed in clinical
trials.
In this study, the non-OSS products were primarily
PEG-based preparations (generally considered to be the
safest available), which constituted 94.9 % of the non-OSS
cohort. Although the incidences for all TEAEs were low
for both cohorts, OSS demonstrated statistically signifi-
cantly lower incidences compared to the non-OSS cohort
for overall TEAEs and major events such as acute cardiac
and serious renal events.
Unlike other bowel preparations, the safety and phar-
macokinetics of OSS have been well studied in patients
with renal and hepatic disease [21]. Unlike sodium phos-
phate preparations, OSS does not lead to formation of
urinary calcium precipitates. Likewise, OSS does not alter
the cardiac QTc interval, which is lengthened by oral
sodium phosphate [22].
Table 3 Adjusted incidence of treatment-emergent adverse events associated with bowel preparations in an adult screening colonoscopy
population
Treatment-emergent adverse event OSS (N = 31,885) Non-OSS (N = 255,438) p value
n Incidence (%) 95 % CI n Incidence (%) 95 % CI
Identified by diagnosis codes
Overall 736 1.61 1.49, 1.74 7374 1.95 1.88, 2.02 \0.001
Acute cardiac conditions or events 499 1.23 1.12, 1.35 4845 1.47 1.41, 1.54 \0.001
Aggravation of gout 75 0.12 0.09, 0.15 715 0.14 0.12, 0.16 0.233
Death 3 0.01 0.00, 0.03 41 0.02 0.01, 0.02 0.369
Ischemic colitis 6 0.02 0.01, 0.04 56 0.02 0.02, 0.03 0.743
Renal failure and other serious renal diseases 67 0.10 0.08, 0.13 817 0.15 0.13, 0.17 0.004
Seizure disorders 85 0.26 0.21, 0.32 859 0.32 0.30, 0.35 0.046
Serum electrolyte abnormalities 125 0.34 0.28, 0.40 1253 0.41 0.38, 0.43 0.048
Identified by laboratory values N = 653 N = 14,432
Elevated creatine kinase 0 0.00 0.00, 0.56 5 0.03 0.01, 0.08 1.000
Serum electrolyte abnormalities and serum uric acid 6 0.86 0.38, 1.91 219 1.37 1.19, 1.58 0.257
Troponin leak 0 0.00 0.00, 0.56 0 0.00 0.00, 0.03 1.000
Adjusted incidence was calculated using Poisson regression, controlling for demographic and clinical risk factors. A factor was removed from the
Poisson model if its parameter estimate was not significant (i.e., p value greater than 0.10). Differences between the two cohorts were tested using
the Wald Chi-square. When there were no events observed, the Clopper–Pearson method was used to calculate exact CIs. The Fisher’s exact test
was used to calculate the p value for troponin leak
CI confidence interval
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Similar to the FDA-approved 4-L PEG preparations,
OSS had only small effects on the balance of stool fluids
and electrolytes [10]. This has not been demonstrated for
other marketed bowel preparations. TEAEs associated with
dehydration such as syncope, hypotension, hyperosmolar-
ity, or electrolyte imbalance were also less frequent or
equivalent relative to the non-OSS cohort. The differences
between OSS and the non-OSS cohorts were not due to
differences in age or observed preexisting medical condi-
tions that were accounted for in the adjusted model.
These results are somewhat surprising as the hypertonic
preparation might be expected to be less safe than the non-
OSS preparations (due to the risk of dehydration if patients
do not consume sufficient supplemental water). The results
reported here are consistent with the clinical study reports
for OSS which showed few adverse events associated with
its use [9]. In this study of 287,323 patients, the overall
incidence for TEAEs was low (unadjusted:\3 %; adjusted:
\2 %), consistent with other reports. Most prior work
focused on serious adverse events and/or those with a GI
basis [23–25]. For example, in a population-based, mat-
ched cohort study of over 50,000 Medicare patients who
underwent outpatient colonoscopy, the overall rate of
serious gastrointestinal and cardiovascular adverse events
was 0.69 and 1.9 %, respectively [12]. However, the lower
incidence of dehydration-related TEAEs associated with
OSS suggests that the instructions for hydration that are
provided with the product, as well as the general practice of
hydration before a colonoscopy, are effective in preventing
dehydration.
A possible limitation of this study is the use of a data-
base of predominantly commercially insured beneficiaries.
However, if the study data captured the true differences
between study cohorts in demographic or clinical risk
factors, results from the Poisson regression analysis should
be applicable to a non-commercially insured population.
Another limitation is that this study was not designed to
detect differences based on different mechanisms. Bowel
cleansing preparations are generally categorized as being
isotonic (such as PEG-ELS) or hypertonic (such as oral
sodium phosphate and OSS).
As expected from prior publications, the incidences of
TEAEs were low in both cohorts [12, 22–25]. The observed
significant differences may not be readily detected and
meaningful at the individual patient level. However,
because colonoscopy is performed in a large number of
patients each year, many patients are at risk and small
differences equate to a meaningful effect on the population
and healthcare system. For example, considering that in
2002, approximately 14 million colonoscopies were per-
formed annually [26], each 0.1 % reduction in TEAE
incidence translates into 14,000 fewer events. If all bowel
preparation products were associated with similar inci-
dences of TEAEs to that of OSS, nearly 60,000 fewer
TEAEs and 50,000 fewer acute cardiac conditions would
be expected to occur each year.
Achieving the highest level of safety during elective
colonoscopy, in otherwise generally healthy people, is a
goal that demands attention. Insurance claims data provide
an excellent means for measuring progress toward that
goal.
The health insurance claims data only included bowel
preparations requiring a prescription. However, nearly half
the bowel preparations in use are over-the-counter (OTC)
preparations, which are generally not FDA-approved
[27–29]. A comparison of TEAEs associated with such
preparations to the approved prescription products is
clearly needed. Given the low incidence of TEAEs asso-
ciated with colonoscopy, small changes in the incidence of
an event are detectable, as shown here.
In this post-marketing study of TEAEs associated with
bowel preparation and screening colonoscopy using a
health insurance claims data source of 287,323 patients, the
adjusted incidence of TEAEs with OSS was low (\2 %),
with fewer overall events, cardiac events, and renal events
than the non-OSS prescription bowel preparations. In
conclusion, this study demonstrates that OSS is as safe as
or possibly safer than non-OSS prescription products under
actual use conditions.
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Table 4 Exhibit 1. Treatment-emergent adverse event definitions and clinical risk factors
TEAE Definition Clinical risk factors
Identified by diagnosis codesa
Ischemic colitis14 Include:
Vascular insufficiency: 557.0, 557.1, 557.9
Exclude:
Preexisting irritable bowel disease: 564.1
Enterectomy within 14 days of vascular insufficiency: 45.6x,
44120, 44121
Crohn’s disease within 14 days of vascular insufficiency:
555.x
Ulcerative colitis within 14 days of vascular insufficiency:
556.x
Clostridium difficile enteritis within 14 days of vascular
insufficiency: 008.45
Noninfectious gastroenteritis after colonoscopy: 558.9x
5-aminosalicylate drug within 14 days of vascular
insufficiency: 54569-0313, 66466-4617, 66467-4617,
66467-4617, 57866-4617, 68258-9086, 59762-0104,
59762-5000, 00179-1407, 00179-1485, 25044-0104,
25044-5000, 00904-1152, 51129-1338, 51129-1408,
51129-2976, 51129-2091, 53489-0147, 66267-0747,
66267-0747, 67651-0038, 55289-0176, 59632-0104,
59632-5700, 53002-0297, 54868-1138, 54868-1138,
54868-1139, 17856-0752, 55154-2305, 55887-0834,
66484-0752, 55289-0833, 59628-0752, 00149-0752,
00615-5515, 55154-5951, 55154-2216, 00088-2010,
54092-0189, 54092-0191, 67209-0191, 59632-0105,
00013-0105, 46603-0122, 53014-0726, 68743-0476,
67209-0476
Colonoscopy/colectomy/surgical pathology of colon biopsy:
88304, 88305, 88307, 88309
Heart failure: 428.0–428.4; 428.9
Hyperlipidemia: 272.0–272.4
Hypotension: 458.X
Vasculitis: 273.2; 287.0; 447.6; 447.8; 695.2
Previous abdominal surgery
Colectomy: (a) CPT: 44139; 44140; 44141; 44143; 44144;
44145; 44146; 44147; 44150; 44151; 44155; 44156; 44157;
44158; 44160; 44204; 44205; 44206; 44207; 44208; 44210;
44211; 44212; 44213; 44799; 45121; b) ICD-9-CM: 17.31;
17.32; 17.33; 17.34; 17.35; 17.36; 17.39; 45.71; 45.72; 45.73;
45.74; 45.75; 45.76; 45.79; 45.81; 45.82; 45.83
Colostomy: a) CPT: 44141; 44143; 44144; 44146; 44188;
44206; 44207; 44208; 44320; 44322; 44340; 44345; 44346;
44605; 44799; 45110; 45111; 45123; 45126; 45395; 45563;
45805; 45825; 46710; 46712; 50810; 51597; 57307; 57308;
58240; 88304; 99505; (b) ICD-9-CM: 45.41; 45.43; 45.6;
46.03; 46.1; 46.10; 46.11; 46.13; 46.14; 46.23; 46.32; 46.39;
46.42; 46.43; 46.52; 46.85; 48.5; 48.62; 68.8; 89.33
Gastric bypass: (a) CPT: 43405; 43610; 43611; 43644; 43645;
43647; 43648; 43651; 43652; 43653; 43659; 43752; 43753;
43754; 43755; 43756; 43757; 43760; 43761; 43770; 43771;
43772; 43773; 43774; 43775; 43800; 43810; 43820; 43825;
43830; 43831; 43832; 43840; 43845; 43846; 43847; 43848;
(b) ICD-9-CM: 43.89; 44.31; 44.38; 44.39; 44.91
Stomach stapling: (a) CPT: 43405; 43610; 43611; 43644;
43846; 43847; b) ICD-9-CM: 44.91
Aggravation of gout Gout: 274.0X, 274.1X, 274.8X, 274.9 Arteriosclerosis: 414.0; 414.3; 440.0–440.4; 440.8; 440.9
Diabetes mellitus: 249.X; 250.X
Hyperlipidemia: 272.0–272.4
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1;
405.9
Thiazide diuretics use: bendroflumethiazide, chlorothiazide,
hydrochlorothiazide, indapamide, metolazone,
methyclothiazide, polythiazide, quinethazone,
trichlormethiazide
Acute cardiac
conditions or events
Abnormal electrocardiogram: 794.31
Acute myocardial infarction: 410.X0, 410.X1, 410.X2
Angina: 413.0, 413.1, 413.9
Arrhythmias: 427.0, 427.1, 427.2, 427.3X, 427.4X, 427.6X,
427.8X, 427.9, 785.0
Cardiac arrest: 427.5
Congestive heart failure: 428.X, 428.2X, 428.3X, 428.4X
Hypotension: 458.0, 458.1, 458.21, 458.29, 458.8, 458.9
Long QT syndrome: 426.82
Shock: 785.5X
Syncope/hypotensive syncope: 780.2
Respiratory arrest: 799.1
Diabetes mellitus: 249.X; 250.X
Hyperlipidemia: 272.0–272.4
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1;
405.9
Thyroid disease: 240.0; 240.9; 241.0; 241.1; 241.9;
242.0–242.4; 242.8; 242.9; 243; 244.0–244.3; 244.8; 244.9;
245.0–245.4; 245.8; 245.9; 246.0–246.3; 246.8; 246.9
Obesity: 278.00, 278.01
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Table 4 continued
TEAE Definition Clinical risk factors
Renal failure and
other serious renal
diseases
Chronic kidney disease: 585.1, 585.2, 585.3, 585.4, 585.5,
585.6, 585.9
Acute kidney injury/acute renal failure/acute phosphate
nephropathy : 584.5–584.9
Unspecified renal failure: 586
Diabetes mellitus: 249.X; 250.X
Heart failure: 428.0–428.4; 428.9
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1;
405.9
Liver disease: 570; 571.0–571.6; 571.8; 571.9; 572.0–572.4;
572.8; 573.0–573.4; 573.8; 573.9
Peripheral artery disease: 443.9
Seizure disorders Tonic–clonic seizures: 345.10, 345.11, 345.3
Loss of consciousness: 780.2
Stroke: 431, 432.0; 432.1; 432.9; 433.0–433.3; 433.8; 433.9;
434.0; 434.1; 434.9; 435.0–435.3; 435.8; 435.9; 436,
437.0–437.9; 438.0–438.9
Brain cancer: 191.X
Serum electrolyte
abnormalities
Electrolyte imbalance: 276.9
Hypercalcemia: 275.42
Hypocalcemia: 275.41
Hypokalemia: 276.8
Hypernatremia: 276.0
Hyponatremia: 276.1
Hypermagnesemia: 275.2
Hypomagnesemia: 275.2
Hyperphosphatemia: 275.3
Osmolality (high): 276.0
Osmolality (low): 276.1
Brain cancer: 191.X
Heart failure: 428.0–428.4; 428.9
Renal disease: 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9,
584.5–584.9, 586
Thiazide diuretics use: bendroflumethiazide, chlorothiazide,
hydrochlorothiazide, indapamide, metolazone,
methyclothiazide, polythiazide, quinethazone,
trichlormethiazide
Identified by laboratory valuesb
Troponin leak Troponin T:[0.09 ng/mL None
Elevated creatine
kinase
Creatine kinase:[ 400 U/(males), 150 U/L (females) None
Serum electrolyte
abnormalities and
serum uric acid
Anion gap = [Na ? K] - ([Cl–] ? [HCO3–]) (high):
[16 mmol/L
Bicarbonate (low):\23 mmol/L
Bilirubin, total (high):[1 mg/dL
BUN (high):[25 mg/dL
Calcium (low):\8.5 mg/dL
Calcium (high):[10.5 mg/dL
Chloride (high):[108 mmol/L
Creatinine (high):[1.5 mg/dL
Magnesium (low):\1.4 mEq/L
Magnesium (high):[2.0 mEq/L
Osmolality (low):\280 mOsm/kg
Osmolality (high):[296 mOsm/kg
Phosphorus (high):[4.5 mg/dL
Potassium (low):\3.4 mmol/L
Sodium (low):\135 mmol/L
Sodium (high):[145 mmol/L
Uric acid elevations:[8.5 mg/dL (males), 6.6 mg/dL
(females)
Electrolyte abnormalities:
Brain cancer: 191.X
Heart failure: 428.0–428.4; 428.9
Renal disease: 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9,
584.5–584.9, 586
Thiazide diuretics use: bendroflumethiazide, chlorothiazide,
hydrochlorothiazide, indapamide, metolazone,
methyclothiazide, polythiazide, quinethazone,
trichlormethiazide
Uric acid:
Arteriosclerosis: 414.0; 414.3; 440.0–440.4; 440.8; 440.9
Diabetes mellitus: 249.X; 250.X
Gout: 274.0X, 274.1X, 274.8X, 274.9
Hyperlipidemia: 272.0–272.4
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1;
405.9
Obesity: 278.00, 278.01
Thiazide diuretics use: bendroflumethiazide, chlorothiazide,
hydrochlorothiazide, indapamide, metolazone,
methyclothiazide, polythiazide, quinethazone,
trichlormethiazide
Renal disease: 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9,
584.5–584.9, 586
a For ischemic colitis, CPT and ICD-9-CM procedure codes for enterectomy and colonoscopy/colectomy/surgical pathology of colon biopsy also
were used in addition to ICD-9-CM diagnosis codes. National Drug Code was used to identify 5-aminosalicylate drugs
b Out-of-range values from Massachusetts General Hospital (MGH) Department of Radiology, MGH Laboratory Handbook: Reference Inter-
vals—MGH Clinical Laboratories. Report generated March 23, 2011. Online Lab Handbook: http://mghlabtest.partners.org
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Table 5 Exhibit 2. Unadjusted incidence of treatment-emergent adverse events comprising the overall categories
Treatment-emergent adverse event (TEAE) SUPREP (N = 31,885) Control (N = 255,438)
n Incidence (%) 95 % CI n Incidence (%) 95 % CI
Identified by diagnosis codes
Acute cardiac conditions or events
Abnormal electrocardiogram 141 0.44 0.38, 0.52 1465 0.57 0.54, 0.60
Acute myocardial infarction 21 0.07 0.04, 0.10 173 0.07 0.06, 0.08
Angina 46 0.14 0.11, 0.19 395 0.15 0.14, 0.17
Arrhythmias 230 0.72 0.63, 0.82 2250 0.88 0.85, 0.92
Cardiac arrest 1 0.00 0.00, 0.02 27 0.01 0.01, 0.02
Congestive heart failure 28 0.09 0.06, 0.13 339 0.13 0.12, 0.15
Hypotension 30 0.09 0.07, 0.13 309 0.12 0.11, 0.14
Long QT syndrome 0 0.00 0.00, 0.01 9 0.00 0.00, 0.01
Shock 5 0.02 0.01, 0.04 50 0.02 0.01, 0.03
Syncope/hypotensive syncope 69 0.22 0.17, 0.27 665 0.26 0.24, 0.28
Respiratory arrest 0 0.00 0.00, 0.01 9 0.00 0.00, 0.01
Renal failure and other serious renal diseases
Chronic kidney disease 42 0.13 0.10, 0.18 532 0.21 0.19, 0.23
Acute kidney failure 26 0.08 0.06, 0.12 317 0.12 0.11, 0.14
Unspecified renal failure 12 0.04 0.02, 0.07 92 0.04 0.03, 0.04
Seizure disorders
Tonic–clonic seizures 3 0.01 0.00, 0.03 41 0.02 0.01, 0.02
Loss of consciousness 82 0.26 0.21, 0.32 821 0.32 0.30, 0.34
Serum electrolyte abnormalities
Electrolyte imbalance 17 0.05 0.03, 0.09 108 0.04 0.04, 0.05
Hypercalcemia 17 0.05 0.03, 0.09 191 0.07 0.06, 0.09
Hypocalcemia 10 0.03 0.02, 0.06 61 0.02 0.02, 0.03
Hypokalemia 55 0.17 0.13, 0.22 573 0.22 0.21, 0.24
Hypermagnesemia or hypomagnesemia 8 0.03 0.01, 0.05 112 0.04 0.04, 0.05
Hyperphosphatemia 0 0.00 0.00, 0.01 34 0.01 0.01, 0.02
Hyperosmolality and/or hypernatremia 4 0.01 0.00, 0.03 32 0.01 0.01, 0.02
Hyposmolality and/or hyponatremia 27 0.08 0.06, 0.12 275 0.11 0.10, 0.12
Identified by laboratory values n = 653 n = 14,432
Serum electrolyte abnormalities and serum uric acid
Anion gap (high) 0 0.00 0.00, 0.56 4 0.03 0.01, 0.07
Bicarbonate (low) 0 0.00 0.00, 0.56 3 0.02 0.01, 0.06
Bilirubin, total (high) 0 0.00 0.00, 0.56 40 0.28 0.20, 0.38
BUN (high) 3 0.46 0.15, 1.42 54 0.37 0.29, 0.49
Calcium (low) 1 0.15 0.02, 1.08 3 0.02 0.01, 0.06
Calcium (high) 0 0.00 0.00, 0.56 16 0.11 0.07, 0.18
Chloride (high) 0 0.00 0.00, 0.56 26 0.18 0.12, 0.26
Creatinine (high) 0 0.00 0.00, 0.56 13 0.09 0.05, 0.16
Magnesium (low) 1 0.15 0.02, 1.08 19 0.13 0.08, 0.21
Magnesium (high) 0 0.00 0.00, 0.56 6 0.04 0.02, 0.09
Osmolality (low) 0 0.00 0.00, 0.56 2 0.01 0.00, 0.06
Osmolality (high) 0 0.00 0.00, 0.56 0 0.00 0.00, 0.03
Phosphorus (high) 0 0.00 0.00, 0.56 2 0.01 0.00, 0.06
Potassium (low) 1 0.15 0.02, 1.08 22 0.15 0.10, 0.23
Sodium (low) 0 0.00 0.00, 0.56 19 0.13 0.08, 0.21
Sodium (high) 0 0.00 0.00, 0.56 9 0.06 0.03, 0.12
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Table 5 continued
Treatment-emergent adverse event (TEAE) SUPREP (N = 31,885) Control (N = 255,438)
n Incidence (%) 95 % CI n Incidence (%) 95 % CI
Uric acid elevations 0 0.00 0.00, 0.56 7 0.05 0.02, 0.10
The unadjusted cumulative incidence of each TEAE was calculated using the Kaplan–Meier method. When there were no events observed, the
Clopper–Pearson method was used to calculate exact CIs
CI confidence interval
Table 6 Exhibit 3. Adjusted incidence of treatment-emergent adverse events comprising the overall categories
Treatment-emergent adverse event OSS (N = 31,885) Non-OSS (N = 255,438)
n Incidence (%) 95 % CI n Incidence (%) 95 % CI
Identified by diagnosis codes
Acute cardiac conditions or events
Abnormal electrocardiogram 141 0.36 0.30, 0.42 1465 0.46 0.42, 0.49
Acute myocardial infarction 21 0.05 0.03, 0.08 173 0.05 0.04, 0.06
Angina 46 0.08 0.06, 0.12 395 0.09 0.07, 0.10
Arrhythmias 230 0.63 0.55, 0.72 2250 0.76 0.72, 0.80
Cardiac arrest 1 0.00 0.00, 0.01 27 0.01 0.00, 0.01
Congestive heart failure 28 0.05 0.03, 0.07 339 0.07 0.05, 0.08
Hypotension 30 0.07 0.05, 0.10 309 0.09 0.07, 0.10
Long QT syndrome 0 0.00 0.00, 0.01 9 0.00 0.00, 0.01
Shock 5 0.02 0.01, 0.04 50 0.02 0.01, 0.03
Syncope/hypotensive syncope 69 0.17 0.14, 0.22 665 0.21 0.18, 0.23
Respiratory arrest 0 0.00 0.00, 0.01 9 0.00 0.00, 0.01
Renal failure and other serious renal diseases
Chronic kidney disease 42 0.07 0.05, 0.09 532 0.10 0.08, 0.11
Acute kidney failure 26 0.04 0.02, 0.06 317 0.05 0.04, 0.06
Unspecified renal failure 12 0.02 0.01, 0.03 92 0.02 0.01, 0.02
Seizure disorders
Tonic–clonic seizures 3 0.01 0.00, 0.03 41 0.02 0.01, 0.02
Loss of consciousness 82 0.25 0.20, 0.31 821 0.31 0.29, 0.33
Serum electrolyte abnormalities
Electrolyte imbalance 17 0.05 0.03, 0.08 108 0.04 0.03, 0.05
Hypercalcemia 17 0.04 0.03, 0.07 191 0.06 0.05, 0.07
Hypocalcemia 10 0.03 0.01, 0.05 61 0.02 0.01, 0.02
Hypokalemia 55 0.14 0.10, 0.18 573 0.17 0.15, 0.19
Hypermagnesemia or hypomagnesemia 8 0.02 0.01, 0.05 112 0.04 0.03, 0.05
Hyperphosphatemia 0 0.00 0.00, 0.01 34 0.01 0.00, 0.01
Hyperosmolality and/or hypernatremia 4 0.01 0.00, 0.03 32 0.01 0.01, 0.02
Hyposmolality and/or hyponatremia 27 0.08 0.05, 0.11 275 0.10 0.08, 0.11
Identified by laboratory values n = 653 n = 14,432
Serum electrolyte abnormalities and serum uric acid
Anion gap (high) 0 0.00 0.00, 0.56 4 0.03 0.01, 0.07
Bicarbonate (low) 0 0.00 0.00, 0.56 3 0.01 0.00, 0.06
Bilirubin, total (high) 0 0.00 0.00, 0.56 40 0.24 0.17, 0.35
BUN (high) 3 0.38 0.12, 1.20 54 0.30 0.22, 0.41
Calcium (low) 1 0.09 0.01, 0.77 3 0.01 0.00, 0.05
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Table 6 continued
Treatment-emergent adverse event OSS (N = 31,885) Non-OSS (N = 255,438)
n Incidence (%) 95 % CI n Incidence (%) 95 % CI
Calcium (high) 0 0.00 0.00, 0.56 16 0.08 0.04, 0.15
Chloride (high) 0 0.00 0.00, 0.56 26 0.18 0.12, 0.26
Creatinine (high) 0 0.00 0.00, 0.56 13 0.06 0.03, 0.11
Magnesium (low) 1 0.15 0.02, 1.05 19 0.12 0.08, 0.19
Magnesium (high) 0 0.00 0.00, 0.56 6 0.04 0.02, 0.09
Osmolality (low) 0 0.00 0.00, 0.56 2 0.01 0.00, 0.05
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